AI assistant
Climb Bio, Inc. — Director's Dealing 2024
Apr 8, 2024
33982_dirs_2024-04-08_99a36848-e1b2-4c3c-948c-ba09f67a6d96.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2024-04-05
Reporting Person: Morisset Valerie (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-05 | Common Stock | M | 17847 | $0.0002 | Acquired | 505307 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-05 | Stock Option (Right to Buy) | $0.0002 | M | 17847 | Disposed | 2031-02-25 | Common Stock (17847) | Direct |
Footnotes
F1: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of February 26, 2021 (the "February 2021 Vesting Commencement Date") and 1/48thof the total number of shares each monthly anniversary of the February 2021 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the February 2021Vesting Commencement Date.